diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM2014181-84diaendo-6303Research ArticleЛекцияLectureВилдаглиптин в клинической практике: анализ сравнительных исследований лекарственных средств с инкретиновой активностьюClinical implementetion of vildagliptin: data from recent studies comparing incretin-based medicationsБирюковаЕлена ВалерьевнаBiryukovaElena Valer'evna

MD, PhD, Professor, Endocrinology Department

lena@obsudim.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry, MoscowRussian Federation2014290320141712014 №18184Copyright © Бирюкова Е.В., 20142014Бирюкова Е.В.Biryukova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6303

С появлением нового класса сахароснижающих препаратов ? группы ингибиторов дипептидилпептидазы-4 (ДПП-4) существенно расширились возможности терапии сахарного диабета (СД) 2 типа. Эта группа препаратов постепенно расширяет свое присутствие в арсенале врача-эндокринолога. Уникальный механизм действия позволяет применять данные препараты как в виде монотерапии, так и в сочетании с традиционными средствами. Информационная база по эффективности и безопасности этой группы постоянно расширяется. Однако до настоящего времени проведено лишь ограниченное число прямых сравнительных исследований препаратов внутри группы. В данной статье представлены некоторые данные из проведенных сравнительных исследований препарата данного класса, вилдаглиптина, с другими представителями группы иДПП-4, а также агонистами рецепторов глюкагоноподобного пептида-1 (ГПП-1).

The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4 inhibitors deepens every year, but to date only a few studies addressed direct comparison between individual agents within this pharmacological class. Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists.

сахарный диабет 2 типаингибиторы ДПП-4инкретинывилдаглиптинdiabetes mellitusDPP-4 inhibitorsincretinsvildagliptinReferencesSchweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabetic Med 2007;24(9):955-961. Available from: http://doi.wiley.com/10.1111/j.1464-5491.2007.02191.x doi: 10.1111/j.1464-5491.2007.02191.x.Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabetic Med 2007;24(9):955-961. Available from: http://doi.wiley.com/10.1111/j.1464-5491.2007.02191.x doi: 10.1111/j.1464-5491.2007.02191.x.Tahrani AA, Piya MK, Barnett AH. Drug evaluation: Vildagliptin-metformin single-tablet combination. Adv Therapy 2009;26(2):138-154. Available from: http://link.springer.com/10.1007/s12325-009-0010-0 doi: 10.1007/s12325-009-0010-0.Tahrani AA, Piya MK, Barnett AH. Drug evaluation: Vildagliptin-metformin single-tablet combination. Adv Therapy 2009;26(2):138-154. Available from: http://link.springer.com/10.1007/s12325-009-0010-0 doi: 10.1007/s12325-009-0010-0.Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. Journal of Diabetes and its Complications 2010;24(2):79-83. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1056872709000075 doi: 10.1016/j.jdiacomp.2009.01.004.Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. Journal of Diabetes and its Complications 2010;24(2):79-83. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1056872709000075 doi: 10.1016/j.jdiacomp.2009.01.004.Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.. J Am Pharm Assoc (2003) 2009;49 Suppl 1(Suppl. 1):16-29. Available from: http://www.nlm.nih.gov/medlineplus/diabetesmedicines.html PubMed PMID: 19801361. doi: 10.1331/JAPhA.2009.09078.Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.. J Am Pharm Assoc (2003) 2009;49 Suppl 1(Suppl. 1):16-29. Available from: http://www.nlm.nih.gov/medlineplus/diabetesmedicines.html PubMed PMID: 19801361. doi: 10.1331/JAPhA.2009.09078.He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2010;48(09):582-595. Available from: http://www.dustri.com/article_response_page.html?artId=7896&doi=10.5414/CPP48582&L=0 PubMed PMID: 20860912. doi: 10.5414/CPP48582.He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2010;48(09):582-595. Available from: http://www.dustri.com/article_response_page.html?artId=7896&doi=10.5414/CPP48582&L=0 PubMed PMID: 20860912. doi: 10.5414/CPP48582.Ischiropoulos H. Biological Tyrosine Nitration: A Pathophysiological Function of Nitric Oxide and Reactive Oxygen Species. Archives of Biochemistry and Biophysics 1998;356(1):1-11. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000398619890755X PubMed PMID: 9681984. doi: 10.1006/abbi.1998.0755.Ischiropoulos H. Biological Tyrosine Nitration: A Pathophysiological Function of Nitric Oxide and Reactive Oxygen Species. Archives of Biochemistry and Biophysics 1998;356(1):1-11. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000398619890755X PubMed PMID: 9681984. doi: 10.1006/abbi.1998.0755.Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care;37(2):587-588. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc14-er02a doi: 10.2337/dc14-er02a.Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care;37(2):587-588. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc14-er02a doi: 10.2337/dc14-er02a.Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).. Cardiovasc Diabetol 2012;11:92. Available from: http://www.cardiab.com/content/11//92 PubMed PMID: 22867630. doi: 10.1186/1475-2840-11-92.Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).. Cardiovasc Diabetol 2012;11:92. Available from: http://www.cardiab.com/content/11//92 PubMed PMID: 22867630. doi: 10.1186/1475-2840-11-92.Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 2012;34(6):1247-1258. Available from: http://dx.doi.org/10.1016/j.clinthera.2012.04.013Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 2012;34(6):1247-1258. Available from: http://dx.doi.org/10.1016/j.clinthera.2012.04.013

The authors declare that there are no conflicts of interest present.